CO2018011663A2 - Nticuerpos anti-basigin humanizados y uso de los mismos - Google Patents

Nticuerpos anti-basigin humanizados y uso de los mismos

Info

Publication number
CO2018011663A2
CO2018011663A2 CONC2018/0011663A CO2018011663A CO2018011663A2 CO 2018011663 A2 CO2018011663 A2 CO 2018011663A2 CO 2018011663 A CO2018011663 A CO 2018011663A CO 2018011663 A2 CO2018011663 A2 CO 2018011663A2
Authority
CO
Colombia
Prior art keywords
humanized anti
antigen
acid sequence
basigin
binding fragment
Prior art date
Application number
CONC2018/0011663A
Other languages
English (en)
Inventor
Zhinan Chen
Ping Zhu
Wan Huang
Zheng Zhang
Yang Zhang
Mengyao Zhang
Huijie Bian
Jianli Jiang
Original Assignee
Fourth Military Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical Univ filed Critical Fourth Military Medical Univ
Publication of CO2018011663A2 publication Critical patent/CO2018011663A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona un anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, que comprende una región variable de cadena pesada (VH) que comprende una secuencia de aminoácidos de la SEQ ID NO: 1; opcionalmente comprende adicionalmente una región variable de cadena ligera (VL) que comprende una secuencia de aminoácidos de la SEQ ID NO: 2. La presente divulgación también proporciona una composición que comprende el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, una secuencia de ácidos nucleicos aislada que codifica el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, un vector que comprende el ácido nucleico, una célula anfitriona que comprende el vector, y uso del anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo.  
CONC2018/0011663A 2016-04-29 2018-10-29 Nticuerpos anti-basigin humanizados y uso de los mismos CO2018011663A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610285139.4A CN105820250B (zh) 2016-04-29 2016-04-29 一种抗basigin人源化抗体及其应用
PCT/CN2017/082713 WO2017186182A1 (en) 2016-04-29 2017-05-02 Humanized anti-basigin antibodies and the use thereof

Publications (1)

Publication Number Publication Date
CO2018011663A2 true CO2018011663A2 (es) 2019-02-08

Family

ID=56528099

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011663A CO2018011663A2 (es) 2016-04-29 2018-10-29 Nticuerpos anti-basigin humanizados y uso de los mismos

Country Status (26)

Country Link
US (1) US20190270809A1 (es)
EP (1) EP3448892A4 (es)
JP (2) JP7099709B2 (es)
KR (1) KR102369118B1 (es)
CN (2) CN105820250B (es)
AU (1) AU2017255888B2 (es)
BR (1) BR112018072140A2 (es)
CA (1) CA3022308A1 (es)
CL (1) CL2018003072A1 (es)
CO (1) CO2018011663A2 (es)
CR (1) CR20180515A (es)
CU (1) CU24556B1 (es)
DO (1) DOP2018000234A (es)
EC (1) ECSP18084153A (es)
IL (1) IL262588A (es)
MA (1) MA44777A (es)
MX (1) MX2018013176A (es)
MY (1) MY196874A (es)
NI (1) NI201800113A (es)
PE (1) PE20190415A1 (es)
PH (1) PH12018502293A1 (es)
RU (1) RU2755150C2 (es)
SG (1) SG11201809473QA (es)
TN (1) TN2018000358A1 (es)
WO (1) WO2017186182A1 (es)
ZA (1) ZA201807132B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
CN111690062A (zh) * 2019-03-14 2020-09-22 复旦大学 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN113549152B (zh) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 一种抗basigin人源化抗体及其应用
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
US7829674B2 (en) * 2006-10-27 2010-11-09 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
CA2688829A1 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
MY148637A (en) * 2007-09-28 2013-05-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A4 (en) 2008-05-23 2012-09-19 Uti Limited Partnership INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS
WO2010087743A2 (en) * 2008-12-30 2010-08-05 Cellartis Ab The use of a protein in stem cell and cancer applications
US20120156221A1 (en) * 2009-06-19 2012-06-21 Ludivine Perrocheau Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
AU2010315243B2 (en) 2009-11-03 2016-08-25 City Of Hope Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection
BR112012013717B1 (pt) * 2009-12-10 2020-01-28 Hoffmann La Roche anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
WO2011112566A2 (en) * 2010-03-11 2011-09-15 Abbott Laboratories Basigin binding proteins
CN104086654B (zh) 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用

Also Published As

Publication number Publication date
AU2017255888B2 (en) 2021-01-07
KR20190020660A (ko) 2019-03-04
KR102369118B1 (ko) 2022-03-03
NI201800113A (es) 2020-01-06
CN109476760A (zh) 2019-03-15
CU24556B1 (es) 2021-12-08
PH12018502293A1 (en) 2019-07-08
RU2755150C2 (ru) 2021-09-13
RU2018138053A (ru) 2020-05-29
ECSP18084153A (es) 2019-03-29
WO2017186182A1 (en) 2017-11-02
IL262588A (en) 2018-12-31
JP2019521648A (ja) 2019-08-08
EP3448892A1 (en) 2019-03-06
ZA201807132B (en) 2021-05-26
BR112018072140A2 (pt) 2019-02-12
MY196874A (en) 2023-05-08
MX2018013176A (es) 2019-06-24
JP7099709B2 (ja) 2022-07-12
US20190270809A1 (en) 2019-09-05
EP3448892A4 (en) 2019-10-16
CN109476760B (zh) 2021-11-12
CN105820250A (zh) 2016-08-03
CA3022308A1 (en) 2017-11-02
CU20180129A7 (es) 2019-06-04
MA44777A (fr) 2019-03-06
CN105820250B (zh) 2019-04-30
CL2018003072A1 (es) 2019-05-31
CR20180515A (es) 2019-05-15
RU2018138053A3 (es) 2020-08-21
AU2017255888A1 (en) 2018-11-22
TN2018000358A1 (en) 2020-06-15
SG11201809473QA (en) 2018-11-29
JP2022084832A (ja) 2022-06-07
PE20190415A1 (es) 2019-03-19
DOP2018000234A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
ECSP18084153A (es) Anticuerpos anti-BASIGIN humanizados y uso de los mismos
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
CR20170026A (es) Anticuerpos anti-tau humanizados
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX2016006529A (es) Anticuerpos dobles especificos.
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
AR105267A1 (es) Anticuerpos de unión a tau
PE20230381A1 (es) Proteina de union a rgma
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
AR108451A1 (es) Anticuerpos anti-tenascina modificados y métodos de utilización